Abstract Iron overload is a major health problem for patients who have to have continuous blood transfusions. It brings some metabolic problems together.
Introduction
Hemochromatosis is a disease which arises from excess iron accumulation in the body and has severe outcomes that may lead to death unless treated. One of the most important causes of the disease is blood transfusions applied to anemia patients. Because anemia requires recurrent blood transfusions due to insufficient hemoglobin, iron overload occurs in liver, heart and other organs. Excess iron deposition is observed in vital organs due to erythrocyte transfusions and degradation of impaired erythrocytes. Therefore all organs, mainly heart and liver may be damaged. So special drugs called chelators (inducing metal excretion) are used to remove the excess iron from the body and to control this condition. Deferasirox (DFX), a new chelator, is effectively used to control iron load. DFX has a high specific affinity to iron. All patients who have iron overload may use DFX comfortably beginning from small ages like 2 years (Karakas 2009). However severe suspects exist about toxic and mutagenic potentials of chelators. In a study done with deferoxamine (DFO), this agent was found to be highly toxic and mutagenic (Whittaker et al. 2001) . DFO together with gamma rays was not only found to be clastogen but it increased genotoxic parameters like frequency of acentric fragment and ring chromosome formation (Juckett et al. 1998 ). In addition, deferiprone, another chelator used to control iron overload in the body, was detected to form chromosom break less frequently than DFO (Marshall et al. 2003) . On the contrary to the abovementioned findings, deferiprone was detected to significantly reduce DNA damage developing as the result of iron deposition (Anderson et al. 2000) . Although DFX which was used as test material in our study has many advantages, sufficient data do not exist about its genotoxicity. Therefore we tried to investigate whether the agent has genotoxic and/or cytotoxic effects using salmonella reversion, RAPD (random amplification of polymorphic DNA) and micronucleus test.
Materials and methods
In this study, deferasirox (Exjade, obtained from a pharmacy in Adana / Turkey) (CAS No: 201530-41-8) was used as test material. Gene mutation test in oxotroph strains of Salmonella typhimurium (TA 98 and TA 100), polymorphic band determination with RAPD test in rat bone marrow cells and human peripheral lymphocytes in vitro micronucleus (MN) test were used as short-term genotoxicity tests. Dimethyl sulfoxide (DMSO) was used as solvent for test material that does not completely dissolve in water. Cells used for quantitative analysis were treated with test material at various concentrations and results were compared with their own controls. LD 50 of the drug and their concentrations used for treatment were taken into consideration for selection of the test material concentration (Scheme 1).
Salmonella reversion test
The standard plate-incorporation assay was performed with S. typhimurium strains TA98 and TA100 in the presence and absence of S9 mix, in accordance with Maron and Ames (1983) . A volume of 0.5 ml S9 mix containing 50 lL of S9 factor per Petri dish was used for the assay. For the test, DFX was dissolved in DMSO and amounts of 108, 216, 432 and 864 lg/petri dish were used. In parallel, 4-nitrophenylene diamine (4-NPD) (cat. no 10,889-8; Sigma-Aldrich, St. Louis; MO, USA), was used as a positive mutagen (100 lg/petri dish) for TA98 and sodium azide (SA) (cat. no S-2002; Sigma) (1 lg/petri dish) for TA100. In addition, 2-aminofluorene (2-AF) (cat. no A-9031; Sigma) was used as a positive mutagen (20 lg/petri) in the presence of S9 mix on both TA98 and TA100 test strains. Each sample was evaluated with five replicate plates.
Experimental animals
Four healthy Sprague-Dawley rats (2 male and 2 female, 12-16 weeks old) were used for each treatment group and the control group. The test animals were maintained under a 14:10-h light:dark photoperiod without twilight at room temperature (25 ± 2°C) and fed by laboratory rodent diet.
In vivo RAPD test
Deferasirox (Exjade) in three different concentrations (250, 500 and 1,000 mg/kg) was administered to the rats via oral gavage (oral LD 50 C 1,000 mg/kg in rats). Each test had one control, one solvent control (DMSO) and one positive control (urethane). 12 or 24 h after deferasirox administration, rats were killed by cervical dislocation under anasthetic conditions. Then bone marrow was aspirated in warm (37°C) isotonic solution (0.9 % NaCI) and then genomic DNA of cells was obtained by using precipitation method with phenol/chloroform and ethanol from cells in each concentration obtained from bone Scheme 1 Skeletal formula of deferasirox marrow samples. Concentrations of the isolated DNA samples were measured using Qubit 2.0 fluorometer device as ng/ll (Schweitzer and Scaiano 2003; McKnight et al. 2006) .
The RAPD protocol was applied by modifying the protocols by Noel and Rath (2006) . Selected primers consisting of 10 nucleotides were used for RAPD-PCR (polymerase chain reaction). Reactions were done at thermocycler (Techne TC 4000). Reaction products were stored at 4°C before electrophoresis. Amplified DNA fragments were separated by electrophoresis procedure (at 85 V for 2 h and 30 min in 1.5 % agarose gel). At the end of this procedure, amplified RAPD profiles obtained with below primers were photographed with Vilber Lournat gel imaging system. Polymorphic band profiles were evaluated in order to explain the differences between RAPD profiles of groups treated with various doses of deferasirox. Differences between the band profiles of treatment groups compared with the band profile formed on the control were determined with the scoring method (decrease or increase in band number) and statistical analysis was done.
Data obtained with the scoring were plotted and evaluated with the t test in the Minitab Ò 15.1.1.0. statistical program. Statistical analysis is based on dividing total polymorphic band counts (N = 590 in this study) of each treatment group with bands obtained with all primers.
Selected primers for RAPD test
In vitro micronucleus test Whether iron chelator deferasirox (Exjade) is genotoxic or not was investigated with the micronucleus test in human peripheral lymphocytes in vitro. For this purpose, human peripheral lymphocytes were treated with deferasirox at three different concentrations (10, 20 and 40 lg/ml) for 24 or 48 h. In vitro micronucleus test was conducted using peripheral blood of two volunteer men and two volunteer women (a total of four subjects) who were healthy, non-smokers, whose BMIs were within normal ranges (18.5-24.9) (Eknoyan 2008 ) and whose ages were close to each other (age of 23-24 years).
The method of Rotfuss et al. (1986) was modified for the in vitro micronucleus test. For this purpose, 0.2 ml of peripheral blood obtained from healthy subjects was inoculated onto 2.5 ml of chromosome medium (PbMax, Gibco, Invitrogen, Carlsbad, CA, USA) and incubated at 37°C for 68 h. Dissolver control (DMSO) 10 ll/2.7 ml medium, positive control (mitomycin-C) 0.25 lg/ml and test material were added to culture medium 20 and 44 h after the beginning of the culture. 10 lg/ml cytochalasin was added to the culture 44 h after the beginning of the incubation.
At the end of incubation, culture tubes were centrifuged (2,000 rpm 5 min), supernatant was thrown away and hypotonic solution (0.4 % KCI) at 37°C was added drop by drop to the cells remaining at the bottom of the tube and the cells were let to swell with incubation at 37°C for 5 min. Cell culture was centrifuged after treatment with hypotonic solution (1,200 rpm 10 min), supernatant was thrown away and cold first fixative (1/5/6 = glacial acetic acid/methanol/ % 0.9 NaCI) was added and the cells were fixed at room temperature for 20 min. After the incubation, the culture tube was centrifuged, supernatant was thrown away and cells were treated with cold second fixative (1/5 = glacial acetic acid/methanol) at room temperature for 20 min. Treatment with the second fixative was repeated once more and preparations were prepared after fixation. Preparations were stained with 5 % Giemsa prepared in Sorensen buffer for 10 min and closed with Entellan Ò . 1,000 binuclear cells were examined to detect cells with micronucleus in preparations prepared from blood cultures of each group (belonging to each control and treatments). A total of 1000 intact cells were scored to determine the frequency of cells, with 1, 2, 3, or 4 nuclei, and to calculate the NDI (nuclear division index) for cytotoxicity of agents using the formula: NDI = ((1 x M1) ? (2 x M2) ? (3 x M3) ? (4 x M4))/N; where M1-M4 represent the number of cells with one to four nuclei and N is the total number of intact cells scored (Fenech 2000) .
Results

Salmonella reversion test
The potential of deferasirox to cause gene mutation was tested at four non-toxic concentration (108, 216, 432 and 864 lg/petri) in absence or presence of metabolic activator (S9 mix). In absence of metabolic activator, all DFX doses except the lowest dose significantly increased reversion mutations compared to dissolver control in the TA 98 strain. In presence of metabolic activator, both untreated control and solvent control led to an increase in the revertant colony number except for the lowest concentration. In the tests done in absence of metabolic activator in TA 100 strain, two low concentrations (108 and 216 lg/petri dish) have led to increase in the number of revertant colonies compared to control and solvent control. The number of colonies decreased compared to controls probably due to toxicity at two high concentrations. In the studies done in presence of metabolic activator, revertant colony number increased compared to control and dissolver control at all concentrations. However, increase of revertant colony number was found statistically significant at two concentrations (216 and 864 lg/petri) ( Table 1) .
RAPD test
According to the obtained results, all untreated control values were accepted as zero in band scoring, all of the comparisons with this control were found significant. When band differences in these groups were evaluated, a very high band polymorphism was found compared to both dissolver control and positive control in rat bone marrow cells in all DFX doses applied for 12 h and the difference was statistically very significant (P \ 0.001) (Fig. 1) . However a significantly higher band polymorphism was detected compared to dissolver control and positive control only for the highest dose (1,000 mg/kg) in 24 h applications (Table 2) .
Micronucleus test
MN fromation was found significantly high compared to controls in the culture treated with the highest dose (40 lg/ml) of DFX in the 48 h period (Table 3) . In this test, the positive control MMC increased micronucleus formation very much in all applications as expected.
The nuclear divison index decreased in the cultures treated with DFX. However this decline was found to be significant compared to control and dissolver control at the two highest concentrations (20 and 40 lg/ml) of the 48 h treatment. Both 24 h and 48 h DFX applications reduced the NDI value at the highest concentration (40 lg/ml) to the level of the positive control (Table 3) . Significant difference with solvent control (a), positive control (b). a1b1: P \ 0.05; a2b2: P \ 0.01; a3b3: P \ 0.001
The DNA of the female rats, RAPD-PCR was performed with Primer 8 (PM8). 1 DNA Marker (from top to bottom: 3,000, 2,000, 1,500, 1,200, 1,000, 900, 800, 700, 600, 500, 400, 300, 200 and 100 bp sized), 2 Control, 3 Solvent Control (DMSO) (12 h), 4 Positive Control (Urethane) (12 h), 5 1000 mg/kg Deferasirox (12 h), 6 500 mg/kg Deferasirox (12 h), 7 250 mg/kg Deferasirox (12), 8 Solvent Control (DMSO) (24 h), 9 Positive Control (Urethane) (24 h), 10 1000 mg/kg Deferasirox (24 h), 11 500 mg/kg Deferasirox (24 h), 12 250 mg/kg Deferasirox (24 h), 13 No DNA
Discussion
In vast majority of the cytogenetic studies done with some chelators, removal of cellular iron was stated to significantly contribute to genome integrity. Of them, deferoxamine (DFO) was reported to show antigenotoxic effect against hydroxyl radical-originated DNA breaks developing as the result of the Fenton/HaberWeiss reaction though the removal of iron from the cell (Anderson et al. 2000; Coogan et al. 1986; Stinson et al. 1992; Beall et al. 1996; Zhang et al. 1996; Witte et al. 2000; Chakrabarti et al. 2001 ).
In our study, DFX shows a mutagen character in S. typhimurium strain. However, it should not be overlooked that the rat S9 liver fraction was used in Salmonella reversion test in this study. There are differences between rat S9 liver fraction and human S9 liver fraction in terms of mutagenic response to procarcinogens (Hakura et al. 2003) . Nevertheless our results are remarkable in order to indicate the genotoxic potential of the test material. In addition, a significantly increased band polymorphism was seen in the in vivo RAPD test done with rat bone marrow cells. However dose-response relationship was not confirmed. Significant increases obtained as the result of the RAPD test support the genotoxic profile of the test material. Band polymorphism significantly increased in bone marrow cell DNA in the 12 h application of test material rather than 24 h application. This result may be related in the in vivo half life (8-16 h) of the agent. Besides, significant increases in the formation of micronuclei were detected in cultured human peripheral lymphocytes. This result is likely related to the clastogenic or aneugenic potential of the test substance. In parallel with these results, an old chelator DFO, showed a highly toxic and also mutagenic effect in L5178Y rat lymphoma cells independently from the presence or absence of S9 (Whittaker et al. 2001) . DFO was detected not to be clastogenic alone but increased the frequency of acentric fragments and ring chromosome formations together with gamma rays (Juckett et al. 1998) .
We have detected some important findings about deferasirox genotoxicity. This is probably due to a failure of the DNA repair system. The removal of iron from the cell by deferasirox may have caused defects in DNA repair system. Iron is the cofactor of ribonucleotide reductase (RNR) enzyme responsible for deoxyribonucleotide synthesis. This enzyme is activated in DNA damage or replication delay situations (Elledge and Davis 1989; Elledge et al. 1993; O'Donnell et al. 2010; Dyavaiah et al. 2011) . Removal of cellular iron protects DNA against reactive oxygen attack. However, genotoxic effects may have as result the suppression of RNR enzymes responsible for DNA repair.
In our study, DFX showed a significant cytotoxic effect. This result is highly similar to that of previous studies. For example, in vitro iron salt application in cell cultures of kaposi sarcoma strongly stimulates the cell growth. Iron chelators like DFO, DFX and ciclopirox olamine are reported to block wnt signal and cell proliferation in colorectal cancer cell line (Song et al. 2011) . When antiproliferative effects of iron chelators, DFX and O-trensox were compared in an human hepatocarcinoma cell line and human hepatocyte culture, Deferasirox was detected to be fairly effective in the induction of DNA fragmentation, inhibition of DNA replication and reduction of cell viability. These chelators were reported to block cell cycle in G0-G1 and S phases, respectively. According to these results, DFX has been suggested to have a very effective antitumoral effect in cancer treatment (Chantrel-Groussard et al. 2006) . Similarly, advancement of cell cycle was reported to be dependent on intracellular iron level and chelators reduce cell proliferation by removing iron. This antiproliferative effect was reported to be inhibited in the presence of exogenous iron (Pires et al. 2006 ). As mentioned above, DFX inhibits ribonucleotide reductase enzyme by removing cellular iron and consequently leads to cytotoxicity by impairing DNA synthesis mechanisms (Zhang and Enns 2009) . Supporting these data, excess iron load has been reported to cause hyperproliferation in some cell types and iron chelation was reported to show antiproliferative effects (Brown et al. 2006; SteegmannOlmedillas 2011) . Likewise, DFX affects the synthesis of molecules that play key roles in carcinogenesis like metastasis, cell cycle control, and apoptosis . In another study, DFO and DFX suppressed growth of oesophageal tumour through depleting of iron from the cells ). According to our results, we may state that the test material has shown an antiproliferative property related to iron chelation. This feature is similar to known effects of chemical agents used for cancer treatment. According to this approach, we consider that DFX or similar ones may lead to new horizons in tumor supression by optimizing their antiproliferative effect besides their main function.
